Fundraising FoxWindtree Therapeutics INC /De
OTC: WINTWarrington, US · Delaware corporation · 2 known investors
Find your way into Windtree Therapeutics INC /De
Sign up to see every warm intro you have to Windtree Therapeutics INC /De
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Windtree Therapeutics INC /De team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
MB
Mary B. TempletonExecutive
CE
Craig E. FraserExecutive
LA
Lawrence A. WeinsteinExecutive
KC
Kathryn ColeExecutive
JT
John TattoryExecutive
GC
George CoxExecutiveGeorge Cox is an executive officer at Windtree Therapeutics with over 30 years of experience in biotechnology, pharmaceutical, and medical device leadership. He has managed cross-functional teams through product development and regulatory approval processes, including domestic and international agency inspections.
SS
Steven SimonsonExecutive
RC
Russell Clayton, D.O.Senior Vice President, Research and Development
ML
Michael L. MageeVice President, Quality Operations
JC
John C. CooperPresident and CEO
TC
Thomas C. HoyVice President, Manufacturing Operations
MB
Mary B. Templeton, Esq.Executive
Investors · 2
Agent CapitalinferredWalthamvia Bruce Peacock · board
How we know: board seat on SEC Form D · Not right? Tell us
Panacea VenturereportedSingapore
How we know: the S-1 prospectus · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$52.4M disclosed across 6 of 7 rounds · 2014–2019
▶$26.4MraisedDec 2019 · 5 investors · BiotechnologyRule 506(b)
▶$26.4MraisedDec 2019 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James HuangDirector
- Daniel GeffkenDirector
- Craig FraserExecutive Officer, Director
- John LeoneDirector
- Mary B. TempletonExecutive Officer
- Bruce PeacockDirector
- Brian SchreiberDirector
- Steven SimonsonExecutive Officer
- John TattoryExecutive Officer
- Joseph MahadyDirector
- Offering amount
- $26.4M
- Amount sold
- $26.4M
- Sales commissions
- $324K
- Placement agents
- Rui Jin (HK) Consulting Management Company Limited
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedJan 2019 · 1 investors · BiotechnologyRule 506(b)
▶$1MraisedJan 2019 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Lawrence A. WeinsteinExecutive Officer
- Bruce A. PeacockDirector
- Joseph M. MahadyDirector
- John R. LeoneDirector
- Brian SchreiberDirector
- Craig E. FraserExecutive Officer, Director
- Steven SimonsonExecutive Officer
- George CoxExecutive Officer
- Mary B. TempletonExecutive Officer
- John TattoryExecutive Officer
- James HuangDirector
- Kathryn ColeExecutive Officer
- Offering amount
- $1M
- Amount sold
- $1M
- First sale
- Dec 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.6MraisedJul 2018 · 1 investors · BiotechnologyRule 506(b)
▶$2.6MraisedJul 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Bruce A. PeacockDirector
- Marvin E. RosenthaleDirector
- Steven A. SimonsonExecutive Officer
- Craig E. FraserExecutive Officer, Director
- John R. LeoneDirector
- George CoxExecutive Officer
- Kathryn ColeExecutive Officer
- Lawrence A. WeinsteinExecutive Officer
- Mary B. TempletonExecutive Officer
- Joseph M. MahadyDirector
- John TattoryExecutive Officer
- Offering amount
- $2.6M
- Amount sold
- $2.6M
- First sale
- Mar 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.5MraisedJul 2018 · 1 investors · BiotechnologyRule 506(b)
▶$1.5MraisedJul 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Marvin E. RosenthaleDirector
- Joseph M. MahadyDirector
- George CoxExecutive Officer
- John TattoryExecutive Officer
- Bruce A. PeacockDirector
- Mary B. TempletonExecutive Officer
- Craig E. FraserExecutive Officer, Director
- Lawrence A. WeinsteinExecutive Officer
- John R. LeoneDirector
- Steven A. SimonsonExecutive Officer
- Kathryn ColeExecutive Officer
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- First sale
- Jul 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10.3MraisedNov 2017 · 17 investors · BiotechnologyRule 506(b)
▶$10.3MraisedNov 2017 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mary B. TempletonExecutive Officer
- Lawrence A. WeinsteinExecutive Officer
- John TattoryExecutive Officer
- Marvin E. RosenthaleDirector
- George CoxExecutive Officer
- Bruce A. PeacockDirector
- Craig E. FraserExecutive Officer, Director
- Kathryn ColeExecutive Officer
- John R. LeoneDirector
- Joseph M. MahadyDirector
- Steven A. SimonsonExecutive Officer
- Offering amount
- $10.3M
- Amount sold
- $10.3M
- First sale
- Oct 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10.5MraisedFeb 2017 · 17 investors · BiotechnologyRule 506(b)
▶$10.5MraisedFeb 2017 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mary B. TempletonExecutive Officer
- Craig E. FraserExecutive Officer, Director
- Lawrence A. WeinsteinExecutive Officer
- Kathryn ColeExecutive Officer
- Marvin E. RosenthaleDirector
- Joseph M. MahadyDirector
- Bruce A. PeacockDirector
- John R. LeoneDirector
- John TattoryExecutive Officer
- George CoxExecutive Officer
- Steven A. SimonsonExecutive Officer
- Offering amount
- $10.5M
- Amount sold
- $10.5M
- First sale
- Feb 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.5MofferedOct 2014 · 1 investors · BiotechnologyRule 506(b)
▶$7.5MofferedOct 2014 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Russell Clayton, D.O.Executive Officer
- Michael L. MageeExecutive Officer
- John C. CooperExecutive Officer, Director
- Marvin E. Rosenthale, Ph.D.Director
- Thomas C. HoyExecutive Officer
- John R. LeoneDirector
- Mary B. Templeton, Esq.Executive Officer
- Kathryn ColeExecutive Officer
- John TattoryExecutive Officer
- Bruce A. PeacockDirector
- Thomas F. Miller, Ph.D., MBAExecutive Officer
- Joseph M. MahadyDirector
- Offering amount
- $7.5M
- First sale
- Oct 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are Windtree Therapeutics INC /De's investors?
- Windtree Therapeutics INC /De's investors include Agent Capital, Panacea Venture.
- How much funding has Windtree Therapeutics INC /De raised?
- Windtree Therapeutics INC /De has disclosed $52.4M raised across 6 of its 7 known rounds.
- Where is Windtree Therapeutics INC /De headquartered?
- Windtree Therapeutics INC /De is headquartered in Warrington, US.